AMAG Pharmaceuticals, Inc. (AMAG)
| Market Cap | 477.47M |
| Revenue (ttm) | 303.03M |
| Net Income (ttm) | -229.17M |
| Shares Out | 34.48M |
| EPS (ttm) | -6.77 |
| PE Ratio | n/a |
| Forward PE | 30.49 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Nov 16, 2021 |
| Last Price | $13.75 |
| Previous Close | $13.75 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 13.75 - 13.76 |
| Day's Volume | 0 |
| 52-Week Range | 4.41 - 13.80 |
News
NEW YORK, Nov. 4, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the ...
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 20, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the...
LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") announced the commencement of a cash tender offer to purchase all of the outstanding shares of com...
WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Dru...
NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New...
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AMAG Pha...
NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the f...
WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the ...
AMAG (AMAG) is set to be acquired by Covis Group for approximately $647 million.
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc. ("A...
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the ...
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) and its board of directors concerning t...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) to Covis Group S.à r.l. (“Covis”)...
The company is being gobbled up by another drugmaker.
New York, New York--(Newsfile Corp. - October 1, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased AMAG Pharmaceuticals, Inc. (...
Addition of AMAG’s category leading treatments positions Covis to become a global market leader of therapeutic solutions for life-threatening conditions and chronic illnesses
WALTHAM, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Scott Myers, Chief Executive Officer, and Brian Piekos, Chief Financial Offi...
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock?
AMAG Pharmaceuticals (AMAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q2 2020 Results - Earnings Call Transcript
AMAG (AMAG) posts a narrower-than-expected loss and revenues miss estimates in the second quarter of 2020.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 16.67% and -6.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the s...
Financial guidance reissued to include EBITDA-positive projection for second-half 2020
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vyleesi® returned to Palatin Technologies
AMAG Pharmaceuticals (NASDAQ: AMAG) shares are trading lower after the company announced it has entered into an exclusive licensing agreement with B.V.
Agreement provides AMAG with $30 million upfront payment and eligibility to receive up to $260 million in development and commercial milestones in addition to sales royalties
Data from two Phase 2 randomized, placebo-controlled, dose-ranging studies using ciraparantag demonstrate efficacy and safety in the reversal of apixaban and rivaroxaban Data from two Phase 2 ...
Company initiates CFO & COO succession plan; appoints internal seasoned finance leader as interim CFO
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock?
Transaction allows AMAG to advance its strategic focus on Feraheme, Makena and its pipeline, consistent with previously announced plans
AMAG Pharmaceuticals' (AMAG) loss narrows year over year while sales top estimates in the first quarter of 2020. The company scraps 2020 outlook due to the plaguing pandemic effect.
AMAG Pharma: Shedding Lackadaisical Segments And Management - Becoming A Focused, Undervalued Pure Play
AMAG Pharmaceuticals, Inc. (AMAG) CEO Scott Myers on Q1 2020 Results - Earnings Call Transcript
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -4000.00% and 5.72%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for th...
Nearly one year after the launch of a drug that increases women's sexual desire, this company's efforts to market it have faltered.
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today provided an update regarding the potential impact of COVID-19 on the company. AMAG is commi...
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock?
Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
AMAG (AMAG) posts a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.
The drugmaker had more bad news than good news in its latest quarterly update.
AMAG Pharmaceuticals, Inc. (AMAG) CEO Bill Heiden on Q4 2019 Results - Earnings Call Transcript
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -2.94% and 1.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...
Conference call scheduled for 8:00 a.m. EST today Conference call scheduled for 8:00 a.m. EST today
WALTHAM, Mass., March 04, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced changes to its medical development organization. Effective March 31, 2020, Julie ...
AMAG is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
AMAG Pharmaceuticals (AMAG) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
About AMAG
AMAG Pharmaceuticals, a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of prete... [Read more...]
| Industry Biotechnology | Founded 1981 |
| CEO Scott D. Myers | Employees 440 |
| Stock Exchange NASDAQ | Ticker Symbol AMAG |
Financial Performance
In 2019, AMAG's revenue was $326.55 million, a decrease of -30.82% compared to the previous year's $472.05 million. Losses were -$467.66 million, 582.7% more than in 2018.